Benzinga
22 Jun 2026, 17:27 UTC · 17w ago
Impact · against what's priced in
Praxis Precision Medicine receives a positive catalyst as the FDA grants Breakthrough Therapy Designation to elsunersen for SCN2A-DEE. The combination of strong Phase 1/2 efficacy data and a streamlined pivotal study design accelerates the path toward potential first-in-class market entry.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA granted Breakthrough Therapy Designation to Praxis Precision Medicine's elsunersen for the treatment of SCN2A-DEE.
More positive than 94% of claims this week
Phase 1/2 EMBRAVE Part A trial results showed elsunersen improved clinical measures in all treated pediatric patients with no drug-related serious adverse events.
Continue reading
5 related stories
The FDA's Breakthrough Therapy Designation and positive Phase 1/2 data showing improvements in clinical measures for all treated pediatric patients significantly reduce regulatory and clinical risk for elsunersen.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 88% of claims this week
Praxis has modified the pivotal EMBRAVE3 study to a single-arm, baseline-controlled design and is currently enrolling approximately 30 patients.
More positive than 68% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received FDA Breakthrough Therapy Designation for its seizure drug following positive trial results, leading to a share price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
4h ago
−9.2%
Price is moving against the score
$256.47 vs $282.31 close before publication (Jun 18) · not market-adjusted
PRAX chart →
